Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Consensus Price Target of $10.00 According to Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $10.00.

Several research analysts have recently weighed in on AUTL shares. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. HC Wainwright assumed coverage on shares of Autolus Therapeutics in a report on Monday, November 2nd. They issued a “buy” rating on the stock. Finally, Weiss Ratings downgraded shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 3rd.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Syncona Portfolio Ltd bought a new position in shares of Autolus Therapeutics during the 2nd quarter worth approximately $26,625,152. Alphabet Inc. acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth approximately $1,117,000. Privium Fund Management B.V. raised its stake in Autolus Therapeutics by 29.2% in the 3rd quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock valued at $911,000 after acquiring an additional 106,060 shares during the period. Cetera Investment Advisers raised its stake in Autolus Therapeutics by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock valued at $1,558,000 after acquiring an additional 29,324 shares during the period. Finally, Waverly Advisors LLC bought a new stake in Autolus Therapeutics in the 1st quarter valued at $37,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $1.28 on Monday. Autolus Therapeutics has a 1-year low of $1.18 and a 1-year high of $2.58. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04. The firm has a fifty day simple moving average of $1.80 and a 200 day simple moving average of $1.66. The stock has a market capitalization of $340.68 million, a PE ratio of -1.21 and a beta of 2.32.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. On average, research analysts expect that Autolus Therapeutics will post -0.76 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.